Tom Powles
@tompowles1
Interested in Urology Cancers, biomarkers and drug development.
ID:1206580727296544769
16-12-2019 14:24:22
1,3K Tweets
10,7K Followers
59 Following
Follow People
Annual meeting of the CARE 1 metastatic 1st line RCC study which is open in France 🇫🇷 and will open in 🇬🇧 soon. Biomarker driven trial (PD-L1) of ipi/nivo vs VEGF/PD1 Laurence Albiges . The Barts team in Paris enjoying the sunshine !!
Presented by Rebecca Dent at #ESMOBreast24 w/ simultaneous publication in Annals of Oncology 1st results of Impassion132 showing no benefit of adding #atezoliyumab to 1st line CT in pts w/ advanced #TNBC relapsing <12months.
#AnnOnc #BreastCancer tinyurl.com/5n99udja
Bravo to Annals of Oncology, a high-impact important journal in our field, for synchronizing the publication of a negative trial. Amplifying our wins is only valuable if we also discuss when we come up short. #ESMOBreast24 Rebecca Dent
🎧 Catch this Uromigos episode (@tompowles1, Brian Rini, MD) on side effects in patients with #metastatic hormone-sensitive #ProstateCancer .
👉 Featuring: Christopher Sweeney, MBBS, Matthew A. Smith, ONCODOC, and Dr. Lisa Horvath
👂 Listen Now: buff.ly/4bVmLh9
Supercharged for the next #Uromigos meeting where we will defend our rights to the cup! Sumanta K. Pal, MD, FASCO Petros Grivas Uromigos
Tom Powles Incredibly important trial, not only for melanoma but for all cancers using (or testing) peri-operative IO. Excited to see the results of this extraordinary accomplishment! Christian Blank Matt Galsky
“The TIME Magazine 100 List for Healthcare? That’s cool & all, and I’m happy for Tom Powles, but I personally have always been after this shiny piece of metal …”
Behold — the Uromigos cup.
#UromigosLive24
#TeamLA : Tanya Dorff Petros Grivas
Uromigos.org
In Annals of Oncology, results of translational analyses studying the predictive and prognostic values of molecular subtypes & genomic alterations 🧬 in the MITO END-3 trial investigating the addition of Avelumab to chemo in metastatic endometrial cancer
annalsofoncology.org/article/S0923-…
Just in JAMA Network Open 👉Our paper on treatment trends and attrition rates for advanced #bladdercancer in the US👉2/3rd of patients did not receive even 2nd-line Rx. Grateful for mentorship by Umang Swami Neeraj Agarwal, MD, FASCO. Link👉 bit.ly/3UHwBgv GU Cancer Research Program @HuntsmanCancer OncoAlert
We are so excited to have the @uromigos back for kidney cancer board review & 2024 updates
First up with Localized RCC discussing risk factors, who needs genetic testing, who qualifies for adjuvant therapy…& who’s a faster swimmer btw Brian Rini, MD & Tom Powles
Which team will win the highly coveted Uromigos #UromigosCup competition to be invited to the #UromigosLive2024 meeting?
👇👇
Sumanta K. Pal, MD, FASCO Petros Grivas Tanya Dorff Neeraj Agarwal, MD, FASCO Toni Choueiri, MD Tian Zhang, MD, MHS
“So I’m backstage with Taylor, and Travis comes up to me and is like - ‘How does it feel to win the Uromigos cup?’”
#UromigosLive24 #SuperbowlOfOncology
#TeamLA : Tanya Dorff Petros Grivas
It has been a fantastic Advanced Prostate Cancer Consensus Conference meeting. Already looking forward to APCCC 2026!
APCCC debate with Thomas Zilli and Pierre Blanchard covering radiation therapy for metastatic disease from Lugano. Thanks to Neeraj Agarwal, MD, FASCO for help with the tweet. #APCCC2024 OncoAlert . t.ly/D7N0_